GSK plc — 6-K Filings
6,008 6-K filings on record
This page lists all 6-K filings submitted to the SEC by GSK plc (GLAXF), sorted by most recent first. Each row links to the full filing on EdgarLookup. GSK plc has filed 6,008 6-K documents with the SEC since 2021. To view all SEC filings by GSK plc, see the full filings list.
All
11-K
13F-HR
20-F
20-F/A
25-NSE
3
3/A
4
4/A
424B2
424B3
5
6-K
6-K/A
8-A12B
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3/A
F-3ASR
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G/A
SD
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | 0001654954-26-002848 | Mar 27, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002851 | Mar 27, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002780 | Mar 26, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002744 | Mar 25, 2026 | — |
| 6-K | NOTICE OF AGM | 0001654954-26-002728 | Mar 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002709 | Mar 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002641 | Mar 24, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002600 | Mar 23, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002577 | Mar 23, 2026 | — |
| 6-K | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | 0001654954-26-002580 | Mar 23, 2026 | — |
| 6-K | ADMISSION TO TRADING | 0001654954-26-002596 | Mar 23, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002514 | Mar 20, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002466 | Mar 19, 2026 | — |
| 6-K | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | 0001654954-26-002482 | Mar 19, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002367 | Mar 18, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002356 | Mar 18, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002324 | Mar 17, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002311 | Mar 17, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002266 | Mar 16, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002208 | Mar 13, 2026 | — |
| 6-K | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | 0001654954-26-002214 | Mar 13, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002183 | Mar 12, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002166 | Mar 12, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002120 | Mar 11, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002076 | Mar 10, 2026 | — |
| 6-K | BOARD COMMITTEE CHANGE | 0001654954-26-002019 | Mar 9, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002005 | Mar 9, 2026 | — |
| 6-K | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | 0001654954-26-002008 | Mar 9, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001950 | Mar 6, 2026 | — |
| 6-K | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | 0001654954-26-001975 | Mar 6, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001907 | Mar 5, 2026 | — |
| 6-K | GSK PUBLISHES ANNUAL REPORT 2025 | 0001654954-26-001917 | Mar 5, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001860 | Mar 4, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001852 | Mar 4, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001790 | Mar 3, 2026 | — |
| 6-K | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | 0001654954-26-001801 | Mar 3, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001756 | Mar 2, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001733 | Mar 2, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001625 | Feb 27, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001650 | Feb 27, 2026 | — |
| 6-K | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | 0001654954-26-001580 | Feb 26, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001575 | Feb 26, 2026 | — |
| 6-K | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | 0001654954-26-001578 | Feb 26, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001551 | Feb 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001531 | Feb 25, 2026 | — |
| 6-K | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | 0001654954-26-001533 | Feb 25, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001547 | Feb 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001477 | Feb 24, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001495 | Feb 24, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001438 | Feb 23, 2026 | — |